Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SIRT1 | Q96EB6 | 16/20 | 0.51 |
| ▸ | SIRT2 | Q8IXJ6 | 12/20 | 0.42 |
| ▸ | BRD4 | O60885 | 2/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7705262 | 0.88 | TSHR (0.47) | SIRT1SIRT2BRD4 | |
| SCHEMBL18144508 | 0.83 | MTNR1A (0.52) | SIRT1BRD4 | |
| SCHEMBL16843718 | 0.83 | MTNR1A (0.52) | SIRT1BRD4 | |
| SCHEMBL18168933 | 0.82 | SIRT1 (0.46) | SIRT1SIRT2BRD4 | |
| SCHEMBL18168894 | 0.82 | SIRT1 (0.46) | SIRT1SIRT2BRD4 | |
| SCHEMBL18168893 | 0.82 | SIRT1 (0.46) | SIRT1SIRT2BRD4 | |
| SCHEMBL6853881 | 0.82 | SIRT1 (0.53) | SIRT1SIRT2 | |
| SCHEMBL18143289 | 0.82 | SIRT1 (0.47) | SIRT1SIRT2 | |
| SCHEMBL19813079 | 0.82 | SIRT1 (0.47) | SIRT1SIRT2 | |
| SCHEMBL18143291 | 0.82 | SIRT1 (0.47) | SIRT1SIRT2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6794385-B2 | ANTITUMOR AGENTS; ANTICANCER AGENTS; OSTEOPOROSIS | PHARMACIA & UPJOHN, S.P.A. (IT) | 2004-09-21 | — | — | US | disclosed |
| US-20030069236-A1 | New benzoxazine derivatives useful as integrin receptor antagonists | PHARMACIA & UPJOHN S.P.A. (IT) | 2003-04-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030069236-A1 | New benzoxazine derivatives useful as integrin receptor antagonists | ITGB1, ITGA1, ITGB3 | SIRT1 639/4885SIRT2 865/4885BRD4 1278/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.